Onc Now | Episode 4
This week, Jonathan Sackier is joined by Sarah Blagden, a pioneer of experimental oncology research, and CEO of RNA Guardian Ltd, a biotechnology company dedicated to identifying early cancer biomarkers.
Spotify | Apple | Amazon Music | Download MP3 (27:11 mins)
Sarah Blagden is the Professor of Experimental Oncology at the University of Oxford, where she leads pioneering research in cancer treatment and molecular biology. As head of the Experimental Oncology Research Group, Sarah focuses on innovative approaches to identify and target cancer at the molecular level. Her impact extends beyond academia: she is also the CEO of RNA Guardian Ltd, a biotechnology company committed to developing early cancer biomarkers that have the potential to transform cancer detection and patient outcomes.
- 00:00 – Introduction
- 01:30 – Recent reads and tweets
- 04:57 – Tweets and cancer acceptance
- 07:36 – Sarah’s journey into oncology
- 09:33 – Exploring new drugs and trials
- 11:48 – Global experiences and improving the clinical trial environment
- 14:28 – Genetics, research, and oncology
- 17:27 – Dysregulation of mRNA translation in cancer
- 18:36 – The future of prevention
- 22:33 – Use of metformin
- 26:36 – Join us for more next time!
